Apply for Gleevec (Imatinib Mesylate) Copay Assistance | QuickRx

Without insurance or copay assistance, brand-name Gleevec can cost over $12,000 per month, with some doses approaching $16,000 per month depending on the strength prescribed. Generic imatinib is typically less expensive but can still range from $150 to several thousand dollars per month without assistance. This high cost puts significant financial strain on patients fighting CML, GIST, Ph+ ALL, or other approved conditions. However, eligible patients may pay as little as $0 through copay assistance programs.

Why is Gleevec so expensive?

Gleevec is a specialty medication that revolutionized cancer treatment as the first targeted tyrosine kinase inhibitor. Used to treat CML, gastrointestinal stromal tumors (GIST), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and rare conditions like dermatofibrosarcoma protuberans (DFSP) and aggressive systemic mastocytosis, Gleevec represents decades of oncology research. The price reflects the complexity of producing targeted cancer therapies.

How QuickRx helps reduce your Gleevec costs:

• Manufacturer copay cards: The Novartis Universal Co-Pay Program can reduce costs to $0 for eligible commercially insured patients on brand Gleevec
• Generic imatinib copay cards: Teva offers a copay card for generic imatinib mesylate that may reduce costs to as little as $0 for commercially insured patients
• Patient assistance programs: The Novartis Patient Assistance Foundation provides free Gleevec to qualifying uninsured patients
• Foundation grants: Disease-specific foundations may provide additional financial support for CML and GIST patients
• Generic alternatives: Generic imatinib is FDA-approved and therapeutically equivalent to Gleevec

QuickRx provides all copay assistance services completely free of charge. Call (917) 830-2525 to find out how much you could save on Gleevec or imatinib.

Yes, generic imatinib mesylate is widely available and may offer significant cost savings compared to brand-name Gleevec. Generic medications contain the same active ingredient and work the same way as the brand-name version but typically cost less.

Generic imatinib availability:

Generic imatinib mesylate has been available since 2016 and is offered in 100 mg and 400 mg tablets from multiple FDA-approved manufacturers. An oral solution formulation, Imkeldi (imatinib 80 mg/mL), is also available for patients who have difficulty swallowing tablets. Your oncologist and pharmacist can help determine which formulation is appropriate for your condition. Learn more about generic drugs from the FDA.

Brand Gleevec vs. generic imatinib:

• Same active ingredient: Generic imatinib contains the identical active compound as Gleevec
• FDA-approved equivalence: Generic versions must meet the same safety and efficacy standards
• Potential cost savings: Generic imatinib often costs significantly less than brand Gleevec
• Copay assistance available: QuickRx can help find copay assistance for both brand and generic versions

QuickRx can help determine if generic imatinib is appropriate for your condition and identify copay assistance options for either brand Gleevec or generic imatinib. In many cases, combining generic pricing with the Teva imatinib copay card results in the lowest possible out-of-pocket cost. Call (917) 830-2525 to discuss your options.

Gleevec (imatinib) is FDA-approved to treat several types of cancer and rare blood disorders. As a tyrosine kinase inhibitor, Gleevec works by blocking specific proteins that drive cancer cell growth.

Leukemia indications:

• Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML): In adults and children, in chronic phase. Learn more about chronic myeloid leukemia.
• Ph+ CML in blast crisis, accelerated phase, or chronic phase after failure of interferon-alpha therapy
• Relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) in adults
• Newly diagnosed Ph+ ALL in pediatric patients in combination with chemotherapy

Solid tumor and other indications:

• Kit (CD117)-positive unresectable and/or metastatic gastrointestinal stromal tumors (GIST). Learn more about GIST treatment from the National Cancer Institute.
• Adjuvant treatment of Kit (CD117)-positive GIST following complete gross resection in adults
• Unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans (DFSP) in adults
• Myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements
• Aggressive systemic mastocytosis without D816V c-Kit mutation or with c-Kit status unknown
• Hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFRα fusion kinase

QuickRx provides Gleevec copay assistance for all FDA-approved imatinib indications.

Gleevec is typically taken once daily for chronic phase CML, with doses ranging from 100 mg to 800 mg depending on your specific condition. Following proper administration guidelines is essential for treatment effectiveness and safety.

Gleevec dosing and administration:

• Standard adult chronic phase CML dose: 400 mg once daily; may be increased to 600 mg or 800 mg if needed
• Standard adult accelerated phase or blast crisis dose: 600 mg once daily; may be increased to 800 mg (400 mg twice daily)
• Take with food and water: Always take imatinib with a meal and a large glass of water to reduce stomach irritation
• Same time daily: Taking Gleevec at the same time each day helps maintain steady drug levels
• Doses ≤600 mg: May be given once daily; 800 mg doses should be split as 400 mg twice daily
• Swallow tablets whole: Do not crush, chew, or break Gleevec tablets

Important dietary restrictions:

Avoid grapefruit and grapefruit juice while taking Gleevec. Grapefruit can increase imatinib levels in your body, potentially increasing side effects. Avoid St. John’s Wort, which can decrease imatinib effectiveness. Learn more about grapefruit and drug interactions from the FDA.

If you cannot swallow tablets:

Gleevec tablets may be dispersed in water or apple juice (~50 mL for 100 mg tablets, ~200 mL for 400 mg tablets). Stir until the tablet dissolves and administer immediately. Avoid skin contact with crushed tablets. Imkeldi (imatinib oral solution, 80 mg/mL) is also available for patients who need a liquid formulation.

QuickRx pharmacists are available to answer questions about taking Gleevec correctly. Call (917) 830-2525.

No, QuickRx copay assistance services are always 100% FREE to patients. We never charge for helping you enroll in manufacturer copay cards, patient assistance programs, or foundation grants for Gleevec (imatinib mesylate).

What’s included at no cost:

• Program identification: We research all available Gleevec and imatinib copay assistance options
• Application support: We complete paperwork and submit applications on your behalf
• Insurance verification: We check your benefits and coverage details
• Prior authorization: We coordinate with your doctor for any required approvals
• Ongoing management: We handle renewals and monitor for new savings opportunities
• Refill coordination: We ensure continuous medication supply without gaps

As a specialty pharmacy, QuickRx is reimbursed through normal pharmacy dispensing—we don’t need to charge patients separately for copay assistance services. Our goal is to help as many patients as possible access their Gleevec or imatinib treatment affordably.

Ready to get started? Call (917) 830-2525 or complete our online form for free Gleevec copay assistance.

Yes, Medicare patients have options for reducing Gleevec costs, though they cannot use manufacturer copay cards due to federal anti-kickback regulations. QuickRx helps Medicare patients navigate alternative assistance programs.

Assistance options for Medicare patients:

• Foundation grants: Independent charitable foundations like the PAN Foundation, HealthWell Foundation, The Leukemia & Lymphoma Society, and Good Days provide grants to help cover medication costs for CML, GIST, and Ph+ ALL patients
• State pharmaceutical assistance programs (SPAPs): Some states offer additional prescription assistance for Medicare beneficiaries
• Medicare Extra Help (LIS): Low-income subsidies that reduce Part D costs. Learn more about Medicare prescription drug assistance.
• Novartis Patient Assistance Foundation: May provide free Gleevec to qualifying Medicare patients with limited income

Our patient navigators understand the specific challenges Medicare patients face with specialty medications. We actively monitor foundation grant openings, help complete applications quickly when funds become available, and explore every option to reduce your out-of-pocket costs for Gleevec or imatinib.

Call (917) 830-2525 to discuss Medicare assistance options for Gleevec.

Common side effects of Gleevec include fluid retention (edema), nausea, muscle cramps, diarrhea, fatigue, and skin rash. Most patients tolerate Gleevec well, but it’s important to recognize potential problems early. Your healthcare team will monitor you regularly throughout treatment.

Most common Gleevec side effects:

• Fluid retention and edema: Particularly around the eyes (periorbital edema), legs, and feet — affects up to 76% of patients
• Nausea and vomiting: May be reduced by taking Gleevec with food and a large glass of water
• Muscle cramps and bone pain: Often in legs, feet, and hands
• Diarrhea: Usually manageable with dietary changes or medication
• Fatigue: Feeling tired or weak is common, especially in the first months
• Skin rash: May appear early in treatment; pigmentation changes may occur
• Decreased appetite and weight changes

Serious side effects requiring immediate attention:

• Severe fluid retention: Rapid weight gain (more than 5 pounds in a week) or difficulty breathing
• Heart failure signs: Shortness of breath, swelling in legs, rapid weight gain
• Liver problems: Yellowing of skin or eyes, dark urine, severe fatigue
• Severe infections: Fever, chills, or flu-like symptoms
• Bone marrow suppression: Unusual bruising, bleeding, or extreme fatigue
• Tumor lysis syndrome: Especially in patients with high tumor burden

Contact your healthcare provider immediately if you experience any serious side effects. QuickRx pharmacists are also available at (917) 830-2525 to answer questions about managing Gleevec side effects.

Treatment duration with Gleevec varies based on your specific condition and how well you respond to therapy. Your oncologist will determine the appropriate treatment length based on your individual circumstances.

General treatment duration guidelines:

• Chronic myeloid leukemia (CML): Treatment typically continues indefinitely as long as Gleevec provides benefit. Some patients who achieve deep, sustained molecular responses may be candidates for treatment-free remission (TFR) under careful medical supervision.
• Gastrointestinal stromal tumors (GIST): For metastatic disease, treatment is often indefinite. For adjuvant therapy after surgery, the recommended duration is typically 3 years for high-risk patients.
• Other indications: Duration depends on disease type, response to treatment, and tolerability

Important considerations:

• Regular blood tests and check-ups are important throughout treatment
• Do not stop taking Gleevec without consulting your doctor — stopping treatment prematurely can lead to disease relapse
• Discontinuing CML treatment is generally not recommended outside of a clinical trial or medical supervision

For patients on extended Gleevec or imatinib treatment, QuickRx manages ongoing copay assistance renewals, monitors for new savings programs, coordinates refills, and provides continuous support throughout your treatment journey. Call (917) 830-2525 to speak with a QuickRx patient navigator.

The Novartis Universal Co-Pay Program is a manufacturer-sponsored program that helps eligible commercially insured patients reduce their out-of-pocket costs for brand-name Gleevec. Eligible patients may pay as little as $0 per prescription.

Eligibility requirements:

• Commercial insurance: Must have private or employer-sponsored health insurance
• Prescription coverage: Your insurance must cover Gleevec (even with a high copay)
• U.S. resident: Must live in the United States
• Age requirement: Typically 18 years or older

Who is NOT eligible:

• Medicare, Medicaid, or other government insurance beneficiaries
• Patients whose insurance does not cover Gleevec
• Cash-paying patients without insurance

QuickRx handles the entire enrollment process for the Novartis Universal Co-Pay Program. We verify your eligibility, complete the application, and apply the savings directly to your prescription—you don’t have to submit claims or wait for reimbursement. Call (917) 830-2525 to check your eligibility for the Gleevec copay card.

The Novartis Patient Assistance Foundation (NPAF) is an independent 501(c)(3) program that provides free Gleevec to eligible patients who cannot afford their medication. This program is available for uninsured patients, those with inadequate prescription coverage, and Medicare patients who cannot afford their Part D cost-sharing.

Eligibility requirements:

• No insurance or inadequate coverage: Patients without prescription coverage or whose insurance denies Gleevec
• Income limits: Must meet certain household income requirements (varies by program)
• U.S. resident: Must live in the United States
• Valid prescription: Must have a prescription from a licensed healthcare provider

Patients approved for NPAF receive their Gleevec medication at no cost. The medication is typically shipped directly to the patient’s home or doctor’s office.

QuickRx patient navigators are experienced with the Novartis Patient Assistance Foundation application process for Gleevec. We help gather required documentation, complete applications accurately, and follow up to ensure timely approval. Call (917) 830-2525 to learn more about the Gleevec patient assistance program.

Gleevec works by inhibiting the BCR-ABL tyrosine kinase, the abnormal protein produced by the Philadelphia chromosome that drives uncontrolled cell growth in CML and Ph+ ALL. By blocking this protein, Gleevec slows or stops the growth of cancer cells while minimizing effects on healthy cells.

Mechanism of action:

According to the National Cancer Institute, imatinib is classified as a tyrosine kinase inhibitor (TKI) that:

• Blocks BCR-ABL kinase: The constitutive abnormal gene product of the Philadelphia chromosome found in CML and some ALL cases
• Inhibits other tyrosine kinases: Including KIT (CD117) — which is the target in GIST — as well as PDGFR (platelet-derived growth factor receptor)
• Induces apoptosis: Triggers programmed cell death in cancer cells while sparing healthy tissue
• Targets specific cancer pathways: Rather than affecting all rapidly dividing cells like traditional chemotherapy

Gleevec was the first targeted cancer therapy of its kind, transforming CML from a fatal diagnosis into a manageable chronic condition for most patients. The 10-year overall survival rate for CML patients receiving first-line imatinib is approximately 83.3%, according to long-term studies.

Gleevec interacts with many other medications, so it’s important to tell your doctor and pharmacist about all drugs you take. Imatinib is metabolized by the CYP3A4 enzyme system and also inhibits this pathway, leading to numerous potential drug interactions.

Medications that may increase Gleevec levels (CYP3A4 inhibitors):

• Strong inhibitors: Ketoconazole, itraconazole, clarithromycin, ritonavir
• Grapefruit and grapefruit juice: Should be avoided entirely

Medications that may decrease Gleevec effectiveness (CYP3A4 inducers):

• Rifampin
• Phenytoin
• Carbamazepine
• Phenobarbital
• St. John’s Wort

Other notable interactions:

• Warfarin: Gleevec may increase the anticoagulant effects of warfarin; consider low-molecular-weight heparin instead, or increase INR monitoring
• Acetaminophen (Tylenol): May increase risk of liver toxicity when combined with imatinib
• Live vaccines: Should be avoided during Gleevec treatment due to immune effects

QuickRx pharmacists review your complete medication list to identify potential interactions with Gleevec. We work with your healthcare team to ensure your medications can be taken safely together. Call (917) 830-2525 to speak with a pharmacist about your medications.

Regular lab monitoring is required while taking Gleevec to check for side effects and ensure the medication is working safely. Your healthcare provider will schedule these tests at appropriate intervals.

Common monitoring tests:

• Complete blood count (CBC): Weekly for the first month, biweekly for the second month, then periodically thereafter
• Liver function tests: At baseline and monthly or as clinically indicated
• Kidney function tests: At baseline and periodically thereafter
• Serum electrolytes: Including calcium, phosphorus, potassium, and sodium levels
• Bone marrow cytogenetics: For CML patients at 6, 12, and 18 months
• Thyroid function (TSH): Especially for patients with prior thyroidectomy on thyroid replacement
• Pediatric monitoring: Children require additional monitoring of growth, weight, glucose, and albumin

Report any new symptoms to your healthcare provider, including signs of infection (fever, chills), breathing problems, rapid weight gain, severe fatigue, or unusual bleeding/bruising. Early detection of side effects allows for prompt management and dose adjustment if needed.

Questions about monitoring requirements? Call (917) 830-2525 to speak with a QuickRx pharmacist.

Gleevec should NOT be taken during pregnancy without careful consultation with your healthcare team, as it may cause harm to an unborn baby. Women who could become pregnant should use highly effective contraception during treatment and for a period after stopping Gleevec.

Important information for women:

• Pregnancy testing: A negative pregnancy test is required before starting Gleevec
• Contraception during treatment: Use highly effective birth control while taking Gleevec
• After stopping treatment: Continue contraception for at least 14 days after your last dose
• Breastfeeding: Breastfeeding is not recommended during treatment or for 1 month after the last imatinib dose, as imatinib and its active metabolite are excreted in breast milk
• Pregnancy detected on therapy: If pregnancy is detected during the first trimester in patients on Gleevec, treatment should typically be discontinued; discuss with your oncologist immediately

Important information for men:

Based on available data, imatinib does not need to be stopped prior to conception in men diagnosed with CML who are planning to father a child. Discuss with your healthcare provider.

Gleevec may affect fertility. Discuss family planning concerns with your healthcare provider before starting Gleevec.

Proper storage of Gleevec helps ensure the medication remains effective throughout your treatment. Follow these storage guidelines carefully.

Storage requirements:

• Temperature: Store at room temperature, 68°F to 77°F (20°C to 25°C); excursions permitted between 59°F to 86°F (15°C to 30°C)
• Moisture: Protect tablets from moisture; avoid bathrooms with high humidity
• Original packaging: Keep in original container until ready to take
• Children and pets: Keep out of reach of children and pets
• Imkeldi oral solution: Discard any remaining amount 30 days after opening

What to avoid:

• Do not freeze: Freezing can damage the medication
• Avoid heat: Do not store near stoves, radiators, or in hot cars
• Skin contact with crushed tablets: If tablets break, avoid direct skin contact and wash thoroughly if contact occurs

Do not flush unused Gleevec down the toilet. Ask your pharmacist about proper disposal methods or FDA-approved drug take-back programs. Learn more about safe medication disposal from the FDA.

Questions about storing your Gleevec? Call QuickRx at (917) 830-2525.

QuickRx Specialty Pharmacy provides comprehensive support for patients taking Gleevec or imatinib, combining expert pharmacy services with dedicated copay assistance help. We’re committed to making your treatment as affordable and convenient as possible.

What sets QuickRx apart:

• Free copay assistance: We never charge for enrollment in savings programs—our copay assistance services are always free
• Dedicated patient navigators: Work with the same team members who know your situation
• Expert pharmacists: Specialized in oncology and specialty medications
• Home delivery: Convenient nationwide shipping directly to your door
• Refill coordination: We proactively manage your prescription to prevent gaps in therapy
• Insurance advocacy: We handle prior authorizations and insurance issues on your behalf

QuickRx is a nationwide specialty pharmacy licensed in all 50 states. We understand that managing CML, GIST, or other serious conditions is challenging enough without worrying about medication costs. Our team is here to help you access the Gleevec or imatinib you need at the lowest possible cost.

Ready to get started? Call (917) 830-2525 to speak with a patient navigator today.

Gleevec, generic imatinib mesylate, and Imkeldi all contain the same active ingredient (imatinib mesylate) but are formulated differently for different patient needs.

Gleevec (Brand-Name Tablets):

Gleevec is the original brand-name imatinib mesylate manufactured by Novartis, FDA-approved in May 2001. Available in 100 mg and 400 mg scored tablets, Gleevec is taken with food and water at the same time each day. The Novartis Universal Co-Pay Program is available for commercially insured patients.

Generic Imatinib Mesylate (Tablets):

Generic imatinib has been available since 2016 from multiple FDA-approved manufacturers. Generic imatinib contains the identical active ingredient and meets the same FDA bioequivalence and therapeutic equivalence standards as brand Gleevec. Generic imatinib copay cards are available for commercially insured patients and may reduce out-of-pocket costs to as little as $0.

Imkeldi (Imatinib Oral Solution):

Imkeldi is an oral solution formulation of imatinib (80 mg/mL) FDA-approved for patients who have difficulty swallowing tablets. This formulation is particularly useful for pediatric patients or adults with swallowing difficulties. Special handling is required:

• Disposable gloves should be worn when handling
• Use the provided oral syringe — do not measure with household teaspoons
• Discard remaining solution 30 days after opening

QuickRx dispenses all three formulations and provides copay assistance for each. Call (917) 830-2525 to discuss which imatinib product is right for you.

Before starting Gleevec, it’s important to share your complete medical history with your healthcare provider. This helps ensure imatinib is safe for you and allows your doctor to monitor for potential complications.

Current health conditions to discuss:

• Active infections or recent illness: Imatinib can suppress the immune system
• Liver or kidney disease: May require dose adjustments
• Heart problems: Including heart failure, coronary artery disease, or arrhythmia
• Hepatitis B infection: May reactivate during treatment; screening is recommended
• Thyroid disease: Especially if you’ve had a thyroidectomy and take levothyroxine
• Diabetes or blood sugar problems: Imatinib can affect glucose levels
• Lung or breathing problems: Risk of fluid retention and pneumonitis
• History of gastric surgery: May reduce imatinib absorption

Pregnancy and fertility considerations:

• Pregnancy status: Pregnancy testing required before starting treatment
• Family planning: Discuss fertility impacts and contraception requirements
• Breastfeeding: Must discontinue breastfeeding during treatment

Bring a complete list of all prescription medications, over-the-counter drugs, vitamins, and herbal supplements. Many products interact with imatinib, including St. John’s Wort, grapefruit products, acetaminophen, ibuprofen, and warfarin.

QuickRx pharmacists can help review your medication list for potential interactions. Call (917) 830-2525.

If you miss a dose of Gleevec, take it as soon as you remember unless it’s almost time for your next dose. Maintaining consistent blood levels of imatinib is important for treatment effectiveness.

Adult patients:

• Remember soon after: Take the missed dose as soon as you remember
• Close to next dose: If it’s almost time for your next dose, skip the missed dose
• Never double dose: Do not take two doses at the same time to make up for a missed dose

Pediatric patients:

• Skip missed dose: For children taking imatinib, skip the missed dose entirely
• Take next scheduled dose: Administer the next scheduled dose at the regular time
• Never double dose: Do not double up doses to make up for a missed dose

Tips to avoid missing doses:

• Take your medication at the same time every day, with food
• Use a pill organizer or medication reminder app
• Set daily alarms on your phone
• Keep your medication in a visible location (away from children and pets)
• Order refills early through QuickRx to avoid gaps

If you frequently miss doses or have questions about your dosing schedule, contact your healthcare provider or call QuickRx at (917) 830-2525. Poor adherence is one of the leading causes of treatment failure in CML — we’re here to help.

Yes! QuickRx dispenses Gleevec and imatinib for pediatric patients with newly diagnosed Ph+ CML or Ph+ ALL, and provides free copay assistance services for families. We understand the unique challenges families face when a child requires long-term targeted cancer therapy.

Pediatric Gleevec assistance options:

• Manufacturer copay programs: Eligible commercially insured pediatric patients may qualify for the Novartis Universal Co-Pay Program
• Imkeldi oral solution: For children who cannot swallow tablets, QuickRx dispenses imatinib oral solution (80 mg/mL) with appropriate copay support
• Patient assistance programs: For uninsured or underinsured pediatric patients
• Pediatric oncology foundations: Including The Leukemia & Lymphoma Society and pediatric-focused grant programs

Why families choose QuickRx for pediatric Gleevec:

• Pediatric pharmacy expertise: Our pharmacists understand age- and weight-based imatinib dosing (typically 340 mg/m²/day for pediatric Ph+ CML)
• Coordination with pediatric oncology teams: We work directly with your child’s care team
• Growth and development monitoring support: We help families track regular monitoring requirements
• Home delivery: Convenient nationwide shipping
• Family-centered care: We understand parents need extra support and information

Pediatric patients on long-term imatinib require monitoring for growth and development. Discuss any concerns with your child’s oncologist throughout treatment.

Need pediatric Gleevec copay assistance? Call (917) 830-2525 to speak with a QuickRx specialist familiar with pediatric oncology.